Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, Alessandra Tedeschi et al.|New England Journal of Medicine|2015Cited by 1.6k
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantationPanagiotis Kottaridis, Stephen Mackinnon, Donald Milligan et al.|Blood|2000Cited by 502
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studiesReuben Benjamin, Jackie Chappell, Marcela V. Maus et al.|The Lancet|2020Cited by 358
<scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A. Eyre, Anna Schuh, Ruth Clifford et al.|British Journal of Haematology|2016Cited by 66
Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib ExposureAndy C. Rawstron, Peter Hillmen, Talha Munir et al.|Blood|2018Cited by 7